IDH1 and glioblastoma: Notably, as diagnostic criteria evolution has introduced prognostic complexities: the 2021 WHO classification now defines GBM specifically as IDH-wildtype (IDHwt) tumors (5), earlier clinical trials, however, included IDH-mutant cases, potentially yielding more optimistic survival outcomes than those expected in trials conducted under current diagnostic standards.